Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells.
Atorvastatin is a new HMG-CoA reductase inhibitor that strongly lowers plasma cholesterol and triglyceride (TG) levels in humans and animals. Since previous data indicated that atorvastatin has… Expand
Differential effects of YM440 a hypoglycemic agent on binding to a peroxisome proliferator-activated receptor gamma and its transactivation.
- E. Kurosaki, R. Nakano, +5 authors H. Shikama
- Chemistry, Medicine
- Biochemical pharmacology
- 1 March 2003
Peroxisome proliferator-activated receptor (PPAR) gamma is a ligand-inducible transcription factor mediating glucose and lipid metabolism. Prior studies showed that YM440 ameliorated hyperglycemia in… Expand
Reduction in hepatic non-esterified fatty acid concentration after long-term treatment with atorvastatin lowers hepatic triglyceride synthesis and its secretion in sucrose-fed rats.
- T. Funatsu, M. Goto, +6 authors K. Miyata
- Biology, Medicine
- Biochimica et biophysica acta
- 28 February 2002
The mechanism by which atorvastatin lowers plasma triglyceride (TG) levels is mainly through a decrease in hepatic TG secretion. However, it is not clear why atorvastatin, which does not inhibit TG… Expand
Pervanadate stimulation of wortmannin-sensitive and -resistant 2-deoxyglucose transport in adipocytes.
Pervanadate mimics several distinct insulin effects, including stimulation of hexose uptake in the in vitro system, and reduces the blood glucose level in streptozotocin-treated diabetic rats. It has… Expand
Hypocholesterolemic effects of the LDL receptor gene transcriptional upregulator CP-230821.
- T. Shimokawa, S. Goto, M. Ida, M. Goto, S. Nishijima, T. Kodama
- Biology, Medicine
- Journal of biochemistry
- 1 April 1998
CP-230821 is a novel, potent LDL receptor gene transcriptional upregulator which decreases total plasma cholesterol level. Interestingly, this plasma LDL decrease does not alter hepatic lipid… Expand